The clinical efficacy of a single HDACi is limited in DLBCL, and resistance to HDACis may be related to the upregulation of P21 and P27 or the activation of the B‐cell receptor (BCR) pathway.13, 14. Here, BCR is linked to diffuse large B-cell lymphoma.